Senior mRNA Design Architect for Therapeutics & Delivery

Emd Group; Billerica (MA); On-site; USD 131,000 - 217,000; Full time

Benefits offered by this job

Health insurance

PTO

Retirement contributions

Perquisites

Job summary

EMD Serono is seeking a Principal Scientist to lead mRNA design and optimization for immunology and oncology applications. This role focuses on end-to-end mRNA construct engineering, regulatory element strategies, and sophisticated sequencing and structural optimization.

The candidate will establish IVT workflows, drive data-driven improvements, and collaborate across R&D teams to advance the LNP platform with translational potential. A PhD with 5+ years in mRNA therapeutics is preferred.

Qualifications

• PhD in RNA Biology or related discipline.
• Typically 5+ years in RNA/mRNA therapeutics or related field.
• In-depth mRNA design and sequence optimization experience.
• Ability to lead multidisciplinary projects independently.

Responsibilities

• Lead design and optimization of mRNA constructs across UTRs, coding sequences and cap structures.
• Establish and run IVT workflows for mRNA synthesis, purification and characterization.
• Lead internal projects advancing mRNA cargo for LNP platform and evaluate sequence/structure effects.
• Present data and study updates in cross-functional meetings.

Skills

mRNA design

Sequence optimization

UTR libraries

Codon optimization

In vitro transcription

LNP delivery

Protein engineering

RNA biology

Education

PhD in RNA Biology

Tools

HPLC

LC-MS

IVT purification

Job description

EMD Serono is seeking a Principal Scientist to lead mRNA design and optimization for immunology and oncology applications. This role focuses on end-to-end mRNA construct engineering, regulatory element strategies, and sophisticated sequencing and structural optimization.

The candidate will establish IVT workflows, drive data-driven improvements, and collaborate across R&D teams to advance the LNP platform with translational potential. A PhD with 5+ years in mRNA therapeutics is preferred.